Close Menu

Forbes' Matthew Herper predicts that the $1,000 genome will become a reality in 2010, "ushering in a new era of genetic medicine." Herper says that direct-to-consumer personalized genomics companies aren't "ready for prime time." Instead, he says that the traditional doctor-insurer-patient model will be more fruitful. The companies on his watch list include Illumina, Complete Genomics, Pacific Biosciences, and Ion Torrent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.